Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.

De Santis M, Lian J, Huang XF, Deng C.

Int J Mol Sci. 2016 Nov 22;17(11). pii: E1944.

2.

Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.

John A, Marchant AL, Fone DL, McGregor JI, Dennis MS, Tan JO, Lloyd K.

Psychol Med. 2016 Dec;46(16):3315-3327.

3.

Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.

Li M.

J Psychopharmacol. 2016 Aug;30(8):749-70. doi: 10.1177/0269881116654697. Epub 2016 Jul 1. Review.

4.

Drug Utilisation Patterns in Children Admitted to a Paediatric General Medical Ward in Five Countries.

Rashed AN, Wong IC, Wilton L, Tomlin S, Neubert A.

Drugs Real World Outcomes. 2015;2(4):397-410. Epub 2015 Nov 18.

5.

System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents.

Murphy AL, Gardner DM, Kisely S, Cooke CA, Kutcher SP, Hughes J.

Clin Child Psychol Psychiatry. 2016 Oct;21(4):634-648. Epub 2015 Nov 27.

6.

Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records.

Downs J, Hotopf M, Ford T, Simonoff E, Jackson RG, Shetty H, Stewart R, Hayes RD.

Eur Child Adolesc Psychiatry. 2016 Jun;25(6):649-58. doi: 10.1007/s00787-015-0780-7. Epub 2015 Oct 15.

7.

A Qualitative Study of Antipsychotic Medication Experiences of Youth.

Murphy AL, Gardner DM, Kisely S, Cooke C, Kutcher SP, Hughes J.

J Can Acad Child Adolesc Psychiatry. 2015 Winter;24(1):61-9. Epub 2015 Mar 4.

8.

Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Chou S, Jones S, Li M.

Brain Res. 2015 Aug 27;1618:122-35. doi: 10.1016/j.brainres.2015.05.036. Epub 2015 Jun 3.

9.

Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.

Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, Sakaeda T, Okuno Y.

Int J Med Sci. 2015 Jan 5;12(2):135-40. doi: 10.7150/ijms.10453. eCollection 2015.

10.

Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents.

Arman S, Sadeghye T, Bidaki R.

Adv Biomed Res. 2014 Nov 29;3:224. doi: 10.4103/2277-9175.145696. eCollection 2014.

11.

Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Shu Q, Qin R, Chen Y, Hu G, Li M.

Behav Brain Res. 2014 Oct 15;273:166-76. doi: 10.1016/j.bbr.2014.07.042. Epub 2014 Aug 2.

12.

Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Saldaña SN, Keeshin BR, Wehry AM, Blom TJ, Sorter MT, DelBello MP, Strawn JR.

Pharmacotherapy. 2014 Aug;34(8):836-44. doi: 10.1002/phar.1453. Epub 2014 Jul 3.

13.

Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood.

Gao J, Li M.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:67-75. doi: 10.1016/j.pnpbp.2014.05.015. Epub 2014 Jun 3.

14.

Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Bachmann CJ, Lempp T, Glaeske G, Hoffmann F.

Dtsch Arztebl Int. 2014 Jan 17;111(3):25-34. doi: 10.3238/arztebl.2014.0025.

15.

Psychotropic medication in children and adolescents.

Lehmkuhl G, Schubert I.

Dtsch Arztebl Int. 2014 Jan 17;111(3):23-4. doi: 10.3238/arztebl.2014.0023. No abstract available.

16.

Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain.

Murphy AL, Gardner DM, Kisely S, Cooke C, Kutcher SP, Hughes J.

ISRN Obes. 2013 Nov 20;2013:390130. doi: 10.1155/2013/390130. eCollection 2013.

17.

The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children.

Dunn AG, Mandl KD, Coiera E, Bourgeois FT.

PLoS One. 2013 Dec 23;8(12):e84951. doi: 10.1371/journal.pone.0084951. eCollection 2013.

18.

Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?

Qiao J, Gao J, Shu Q, Zhang Q, Hu G, Li M.

Psychopharmacology (Berl). 2014 Apr;231(8):1649-1659. doi: 10.1007/s00213-013-3386-0. Epub 2013 Dec 21.

19.

Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.

Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh PJ, Arango C, Kölch M, Coghill D, Flamarique I, Penzol MJ, Wan M, Murray M, Wong IC, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert JM, Vicari S, Carucci S, Dittmann RW, Buitelaar JK; PERS Consortium.

Eur Child Adolesc Psychiatry. 2014 Dec;23(12):1149-60. doi: 10.1007/s00787-013-0498-3. Epub 2013 Dec 15.

20.

Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care.

Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy DG, Asherson PJ, Eklund H, Wong IC.

Psychopharmacology (Berl). 2014 Mar;231(6):1011-21. doi: 10.1007/s00213-013-3140-7. Epub 2013 May 17.

Supplemental Content

Support Center